News

Entera Bio Unveils Promising Phase 2 Results for EB613 Therapy

Entera Bio Unveils Promising Phase 2 Results for EB613 Therapy

Entera Bio Presents New Findings on EB613 Therapy

Entera Bio Ltd. (NASDAQ: ENTX), renowned for its innovative oral peptide and protein replacement therapies, has exciting news to share. The company will present new clinical data concerning its Phase 2 trial of EB613 during the upcoming North American Menopause Society (NAMS) meeting. This presentation signifies a notable milestone as it's Entera’s first appearance at this esteemed event.

A Closer Look at the Phase 2 Trial Results

The Phase 2 data from EB613 focuses specifically on early postmenopausal women who present low bone mass or osteoporosis. This critical subset of patients is often a neglected area in the realm of osteoporosis treatment, as many continue to go without anabolic therapy options. The study zeroes in on the impact of the therapy on bone mineral density outcomes over a comprehensive six-month period.

Rising Risk and Underutilization of Anabolic Therapies

In her remarks, Miranda Toledano, Chief Executive Officer of Entera, highlighted a significant issue in the treatment landscape: anabolic therapies remain underutilized, primarily due to their current administration methods. "Injectable options pose a barrier for many, limiting access to effective treatment," she stated. The introduction of EB613, the first oral anabolic tablet, could transform how treatments are initiated, potentially reaching the 200 million women globally affected by osteoporosis.

Understanding the Significance of Timing in Treatment

At the NAMS meeting, Entera aims to present crucial data regarding the timing of therapeutic interventions, a key question in both clinical practice and market strategy. This could guide physicians on when to introduce anabolic therapy to patients, tapping into a demographic that is significantly at risk yet often underserved.

Details of the Presentation

Here are the essential details for those interested in the presentation:

Conference: North American Menopause Society (NAMS) Annual Meeting

Title: EB613 (Oral PTH[1-34] Tablets) Increases BMD Over 6 Months in Early Postmenopausal Women with Low Bone Mass or Osteoporosis: A Phase 2 Randomized Trial

Presentation Number: P-66

Session Title: Poster Presentation

Session Date/Time: Thursday, October 23, 2025, 06:15 PM - 07:15 PM

Location: Windemere Exhibit Hall

Insights about EB613

Research supports that anabolic treatments are superior in lowering fracture risks for osteoporosis patients compared to anti-resorptive medications. Despite this, current anabolic offerings are limited to injection formats, deterring many eligible patients. EB613 represents a groundbreaking step forward as it is being developed as the first oral, once-daily tablet treatment for osteoporosis. In phase 2 trials involving 161 participants, the medication succeeded in meeting critical biomarker and bone mineral density (BMD) endpoints, all without significant safety concerns.

The Positive Outcomes of EB613

With administration of EB613, participants showed rapid increases in markers associated with bone formation and reductions in those associated with bone resorption. Additionally, notable increases in lumbar spine, total hip, and femoral neck BMD were recorded over the six months of treatment.

About Entera Bio

Entera is committed to pioneering oral peptide and protein replacement therapies that address pressing medical needs. The company’s innovative technology platform, known as N-Tab™, supports its mission to revolutionize the standard of care through oral formulations. The flagship product, EB613, is on track to become the first oral anabolic therapy targeting post-menopausal women at risk for low bone density. Furthermore, Entera is advancing other peptides, including the first oral oxyntomodulin for obesity and a GLP-2 peptide aimed at patients facing malabsorption challenges.

For more insights about Entera Bio's groundbreaking work and initiatives, please reach out to:

Company Contact:
Ms. Miranda Toledano
Chief Executive Officer, Entera Bio
Email: miranda@enterabio.com

Frequently Asked Questions

What is EB613?

EB613 is an oral peptide therapy developed by Entera Bio aimed at treating osteoporosis in postmenopausal women.

When will Entera Bio present its findings?

The presentation of new clinical data is scheduled for October 23, 2025, at the NAMS Annual Meeting.

Why are anabolic therapies important?

Anabolic therapies rebuild bone and reduce fracture risk, yet they are currently underutilized among eligible patients.

What were the results of the Phase 2 trial?

The Phase 2 trial demonstrated increases in bone mineral density and positive shifts in bone formation markers.

How does EB613 differ from current treatments?

EB613 is the first oral anabolic therapy, providing a more accessible treatment option compared to traditional injectable therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
AI Gives CPA Firms a New Advisory Staffing Math Today

Updated Category News Views 26

Month-end just got a lot less comfortable for firms living on the clock. Netsurit and Southwestern Talent are pitching the Virtual CFO Platform as a way for CPA firms to turn machine-led analysis into advisory work without first building a costly bench of specialists. That is not a cute workflow tweak. It goes straight at the labor model that has kept plenty of accounting...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 183

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 123

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 85

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 54

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 31

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 229

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading

Top 5 Most Recently Viewed Articles

Delicious New Dips by Dean's Perfect for Every Snack Lovers

Updated Category News Views 536

Dean's Dip Launches Five Exciting New Flavors Dean's Dip, a well-loved name in the dairy dip sector, is thrilled to introduce its latest flavors, catering to snack aficionados everywhere. In addition to its classic offerings, the brand is now adding two delightful new dips — Creamy Dill and Jalapeño Popper. But that's not all! A fresh sub-line of dips, the Cantina...

Continue Reading
Bavarian Nordic Secures $63 Million for Vaccine Manufacturing

Updated Category News Views 102

Bavarian Nordic Secures New Contract with U.S. Government Bavarian Nordic A/S (Copenhagen: BAVA) has announced an important contract with the U.S. government's Biomedical Advanced Research and Development Authority (BARDA). This order, worth USD 63 million, will enhance the nation's stockpile of smallpox/mpox vaccines and pave the way for producing more freeze-dried doses...

Continue Reading
NewtekOne, Inc. Declares Impressive Quarterly Dividend Update

Updated Category News Views 158

NewtekOne, Inc. Announces Quarterly Dividend Declaration NewtekOne, Inc. (NASDAQ: NEWT) has recently made an exciting announcement for its shareholders. The Board of Directors has declared a quarterly cash dividend amounting to $0.19 per share, which is a testament to the company's ongoing commitment to enhancing shareholder value. As the company gears up for this...

Continue Reading
New Clean Freak Car Wash Location Welcomes Local Community

Updated Category News Views 516

Exciting New Location of Clean Freak Car Wash Clean Freak Car Wash, an innovative company supported by Circle K, is thrilled to announce the grand opening of its latest location. This highly anticipated launch is set to bring exceptional car wash services, designed to provide customers with a refreshing and satisfying experience. Commitment to Quality and Eco-Friendly...

Continue Reading
Bernie Sanders Calls for Action Against Wealth Inequality Surge

Updated Category News Views 200

Bernie Sanders Raises Concerns Over Wealth Disparity Sen. Bernie Sanders has openly criticized the increasing wealth inequality in the country, highlighting the significant gains of a select group of billionaires. His latest remarks reflect deep concern for the financial struggles faced by millions of Americans. Wealth of Billionaires on the Rise In a striking statement,...

Continue Reading